Cargando…

Serial changes in tumour measurements and apparent diffusion coefficients in prostate cancer patients on active surveillance with and without histopathological progression

OBJECTIVE: To analyse serial changes in MRI-derived tumour measurements and apparent diffusion coefficient (ADC) values in prostate cancer (PCa) patients on active surveillance (AS) with and without histopathological disease progression. METHODS: This study included AS patients with biopsy-proven PC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sushentsev, Nikita, Caglic, Iztok, Rundo, Leonardo, Kozlov, Vasily, Sala, Evis, Gnanapragasam, Vincent J, Barrett, Tristan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The British Institute of Radiology. 2022
Materias:	Innovations in prostate cancer special feature : Full Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978242/ https://www.ncbi.nlm.nih.gov/pubmed/34538077 http://dx.doi.org/10.1259/bjr.20210842

Ejemplares similares

MRI-derived PRECISE scores for predicting pathologically-confirmed radiological progression in prostate cancer patients on active surveillance
por: Caglic, Iztok, et al.
Publicado: (2020)

MRI-derived radiomics model for baseline prediction of prostate cancer progression on active surveillance
por: Sushentsev, Nikita, et al.
Publicado: (2021)

Prospective Implementation and Early Outcomes of a Risk-stratified Prostate Cancer Active Surveillance Follow-up Protocol
por: Thankapannair, Vineetha, et al.
Publicado: (2023)

A Feasibility Study of the Therapeutic Response and Durability of Short-term Androgen-targeted Therapy in Early Prostate Cancer Managed with Surveillance: The Therapeutics in Active Prostate Surveillance (TAPS01) Study
por: Barrett, Tristan, et al.
Publicado: (2022)

Comparative performance of MRI-derived PRECISE scores and delta-radiomics models for the prediction of prostate cancer progression in patients on active surveillance
por: Sushentsev, Nikita, et al.
Publicado: (2021)

Time series radiomics for the prediction of prostate cancer progression in patients on active surveillance
por: Sushentsev, Nikita, et al.
Publicado: (2023)

Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium
por: Olivier, Jonathan, et al.
Publicado: (2022)

Active Surveillance for Men Younger than 60 Years or with Intermediate-risk Localized Prostate Cancer. Descriptive Analyses of Clinical Practice in the Movember GAP3 Initiative
por: Remmers, Sebastiaan, et al.
Publicado: (2022)

Comparative performance of fully-automated and semi-automated artificial intelligence methods for the detection of clinically significant prostate cancer on MRI: a systematic review
por: Sushentsev, Nikita, et al.
Publicado: (2022)

Identification and Validation of Leucine-rich α-2-glycoprotein 1 as a Noninvasive Biomarker for Improved Precision in Prostate Cancer Risk Stratification
por: Guldvik, Ingrid J., et al.
Publicado: (2020)

Optimal biopsy approach for detection of clinically significant prostate cancer
por: Ippoliti, Simona, et al.
Publicado: (2022)

Impact of Health-related Quality of Life and Prediagnosis Risk of Major Depressive Disorder on Treatment Choice in Low- and Intermediate-Risk Prostate Cancer
por: Riskin-Jones, Hannah, et al.
Publicado: (2020)

MRI features of the normal prostatic peripheral zone: the relationship between age and signal heterogeneity on T2WI, DWI, and DCE sequences
por: Bura, Vlad, et al.
Publicado: (2021)

Active Surveillance—Is It Feasible for Intermediate-risk Localised Prostate Cancer?
por: Mukherjee, Subhabrata, et al.
Publicado: (2021)

Variations in the Uptake of Active Surveillance for Prostate Cancer and Its Impact on Outcomes
por: Ahlberg, Mats S., et al.
Publicado: (2023)

Real-world Evidence to Estimate Prostate Cancer Costs for First-line Treatment or Active Surveillance
por: Magnani, Christopher J., et al.
Publicado: (2020)

A head-to-head comparison of the intra- and interobserver agreement of COVID-RADS and CO-RADS grading systems in a population with high estimated prevalence of COVID-19
por: Sushentsev, Nikita, et al.
Publicado: (2020)

Fear of Recurrence in Prostate Cancer Patients: A Cross-sectional Study After Radical Prostatectomy or Active Surveillance
por: Nilsson, Rasmus, et al.
Publicado: (2021)

Association Between a 22-feature Genomic Classifier and Biopsy Gleason Upgrade During Active Surveillance for Prostate Cancer
por: Press, Benjamin H., et al.
Publicado: (2022)

Comparison of Characteristics, Follow-up and Outcomes of Active Surveillance for Prostate Cancer According to Ethnicity in the GAP3 Global Consortium Database
por: Beckmann, Kerri, et al.
Publicado: (2021)

Prospective Long-term Health-related Quality of Life Outcomes After Surgery, Radiotherapy, or Active Surveillance for Localized Prostate Cancer
por: Kord, Eyal, et al.
Publicado: (2022)

Clinical Application of the Prostate Cancer Radiological Estimation of Change in Sequential Evaluation Score for Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer
por: Aerts, Jan, et al.
Publicado: (2023)

Does Protocol Make a Difference? Comparison of Two Prostate Cancer Active Surveillance Cohorts: A Non–protocol-based Follow-up and a Protocol-based Contemporary Follow-up
por: Kalalahti, Inari, et al.
Publicado: (2021)

Using a Recurrent Neural Network To Inform the Use of Prostate-specific Antigen (PSA) and PSA Density for Dynamic Monitoring of the Risk of Prostate Cancer Progression on Active Surveillance
por: Sushentsev, Nikita, et al.
Publicado: (2023)

Prostate Cancer Risk Inflation as a Consequence of Image-targeted Biopsy of the Prostate: A Computer Simulation Study
por: Robertson, Nicola L., et al.
Publicado: (2014)

PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate
por: Ferraldeschi, Roberta, et al.
Publicado: (2015)

Focal Therapy: Patients, Interventions, and Outcomes—A Report from a Consensus Meeting
por: Donaldson, Ian A., et al.
Publicado: (2015)

Outcomes and toxicity of 313 prostate cancer patients receiving helical tomotherapy after radical prostatectomy
por: Jensen, Lindsay, et al.
Publicado: (2017)

Serum testosterone changes in patients treated with radiation therapy alone for prostate cancer on NRG oncology RTOG 9408
por: Nichols, R. Charles, et al.
Publicado: (2017)

Risk factors involved in treatment delays and differences in treatment type for patients with prostate cancer by risk category in an academic safety net hospital
por: Kan, Carolyn K., et al.
Publicado: (2017)

Outcomes and toxicity from a prospective study of moderately hypofractionated radiation therapy for prostate cancer
por: Wang, Wei Gang, et al.
Publicado: (2017)

Superior metastasis-free survival for patients with high-risk prostate cancer treated with definitive radiation therapy compared to radical prostatectomy: A propensity score-matched analysis
por: Markovina, Stephanie, et al.
Publicado: (2017)

Withania somnifera root extract inhibits fatty acid synthesis in prostate cancer cells
por: Kim, Su-Hyeong, et al.
Publicado: (2020)

Diversity in Androgen Receptor Action Among Treatment-naïve Prostate Cancers Is Reflected in Treatment Response Predictions and Molecular Subtypes
por: Ben-Salem, Salma, et al.
Publicado: (2020)

Accuracy of Prostate Magnetic Resonance Imaging: Reader Experience Matters
por: Kang, Hyunseon C., et al.
Publicado: (2021)

Docetaxel Treatment for Metastatic Hormone-sensitive Prostate Cancer in Daily Practice
por: de Groot, Ietsen, et al.
Publicado: (2021)

Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA
por: Sumanasuriya, Semini, et al.
Publicado: (2021)

Red Blood Cell Distribution Width Is Associated with All-cause Mortality but Not Adverse Cancer-specific Outcomes in Men with Clinically Localized Prostate Cancer Treated with Radical Prostatectomy: Findings Based on a Multicenter Shared Equal Access Regional Cancer Hospital Registry
por: Orabi, Hazem, et al.
Publicado: (2022)

Treatment Patterns and Overall Survival Outcomes Among Patients Aged 80 yr or Older with High-risk Prostate Cancer
por: Fischer-Valuck, Benjamin W., et al.
Publicado: (2022)

Intervention-related Deaths in the European Randomized Study of Screening for Prostate Cancer
por: Godtman, Rebecka Arnsrud, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_h8j01e8o15b6hv3rn3vsjfe6kr